-+ 0.00%
-+ 0.00%
-+ 0.00%

Analysts Are Updating Their DiaSorin S.p.A. (BIT:DIA) Estimates After Its Third-Quarter Results

Simply Wall St·11/15/2026 08:23:40
Listen to the news

It's been a good week for DiaSorin S.p.A. (BIT:DIA) shareholders, because the company has just released its latest quarterly results, and the shares gained 2.0% to €84.32. It was an okay result overall, with revenues coming in at €308m, roughly what the analysts had been expecting. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

earnings-and-revenue-growth
BIT:DIA Earnings and Revenue Growth November 15th 2026

Following the latest results, DiaSorin's 14 analysts are now forecasting revenues of €1.32b in 2027. This would be a solid 9.3% improvement in revenue compared to the last 12 months. Per-share earnings are expected to jump 35% to €3.94. Before this earnings report, the analysts had been forecasting revenues of €1.31b and earnings per share (EPS) of €3.87 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

Check out our latest analysis for DiaSorin

It will come as no surprise then, to learn that the consensus price target is largely unchanged at €79.63. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on DiaSorin, with the most bullish analyst valuing it at €105 and the most bearish at €55.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. One thing stands out from these estimates, which is that DiaSorin is forecast to grow faster in the future than it has in the past, with revenues expected to display 7.4% annualised growth until the end of 2027. If achieved, this would be a much better result than the 2.1% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 4.7% per year. Not only are DiaSorin's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at €79.63, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for DiaSorin going out to 2028, and you can see them free on our platform here.

Even so, be aware that DiaSorin is showing 1 warning sign in our investment analysis , you should know about...